Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor
IntroductionImmune checkpoint inhibitors have had a major impact on cancer treatment. Gut microbiota plays a major role in the cancer microenvironment, affecting treatment response. The gut microbiota is highly individual, and varies with factors, such as age and race. Gut microbiota composition in...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1164724/full |
| _version_ | 1797834661646303232 |
|---|---|
| author | Kazuyuki Hamada Kazuyuki Hamada Junya Isobe Kouya Hattori Kouya Hattori Masahiro Hosonuma Masahiro Hosonuma Masahiro Hosonuma Masahiro Hosonuma Yuta Baba Masakazu Murayama Masakazu Murayama Masakazu Murayama Masakazu Murayama Yoichiro Narikawa Yoichiro Narikawa Yoichiro Narikawa Yoichiro Narikawa Hitoshi Toyoda Hitoshi Toyoda Hitoshi Toyoda Hitoshi Toyoda Eiji Funayama Kohei Tajima Kohei Tajima Midori Shida Yuya Hirasawa Toshiaki Tsurui Hirotsugu Ariizumi Tomoyuki Ishiguro Risako Suzuki Ryotaro Ohkuma Yutaro Kubota Takehiko Sambe Mayumi Tsuji Mayumi Tsuji Satoshi Wada Yuji Kiuchi Yuji Kiuchi Shinichi Kobayashi Atsuo Kuramasu Atsushi Horiike Yun-Gi Kim Takuya Tsunoda Kiyoshi Yoshimura Kiyoshi Yoshimura |
| author_facet | Kazuyuki Hamada Kazuyuki Hamada Junya Isobe Kouya Hattori Kouya Hattori Masahiro Hosonuma Masahiro Hosonuma Masahiro Hosonuma Masahiro Hosonuma Yuta Baba Masakazu Murayama Masakazu Murayama Masakazu Murayama Masakazu Murayama Yoichiro Narikawa Yoichiro Narikawa Yoichiro Narikawa Yoichiro Narikawa Hitoshi Toyoda Hitoshi Toyoda Hitoshi Toyoda Hitoshi Toyoda Eiji Funayama Kohei Tajima Kohei Tajima Midori Shida Yuya Hirasawa Toshiaki Tsurui Hirotsugu Ariizumi Tomoyuki Ishiguro Risako Suzuki Ryotaro Ohkuma Yutaro Kubota Takehiko Sambe Mayumi Tsuji Mayumi Tsuji Satoshi Wada Yuji Kiuchi Yuji Kiuchi Shinichi Kobayashi Atsuo Kuramasu Atsushi Horiike Yun-Gi Kim Takuya Tsunoda Kiyoshi Yoshimura Kiyoshi Yoshimura |
| author_sort | Kazuyuki Hamada |
| collection | DOAJ |
| description | IntroductionImmune checkpoint inhibitors have had a major impact on cancer treatment. Gut microbiota plays a major role in the cancer microenvironment, affecting treatment response. The gut microbiota is highly individual, and varies with factors, such as age and race. Gut microbiota composition in Japanese cancer patients and the efficacy of immunotherapy remain unknown. MethodsWe investigated the gut microbiota of 26 patients with solid tumors prior to immune checkpoint inhibitor monotherapy to identify bacteria involved in the efficacy of these drugs and immune-related adverse events (irAEs).ResultsThe genera Prevotella and Parabacteroides were relatively common in the group showing efficacy towards the anti-PD-1 antibody treatment (effective group). The proportions of Catenibacterium (P = 0.022) and Turicibacter (P = 0.049) were significantly higher in the effective group than in the ineffective group. In addition, the proportion of Desulfovibrion (P = 0.033) was significantly higher in the ineffective group. Next, they were divided into irAE and non-irAE groups. The proportions of Turicibacter (P = 0.001) and Acidaminococcus (P = 0.001) were significantly higher in the group with irAEs than in those without, while the proportions of Blautia (P = 0.013) and the unclassified Clostridiales (P = 0.027) were significantly higher in the group without irAEs than those with. Furthermore, within the Effective group, Acidaminococcus and Turicibacter (both P = 0.001) were more abundant in the subgroup with irAEs than in those without them. In contrast, Blautia (P = 0.021) and Bilophila (P= 0.033) were statistically significantly more common in those without irAEs.DiscussionOur Study suggests that the analysis of the gut microbiota may provide future predictive markers for the efficacy of cancer immunotherapy or the selection of candidates for fecal transplantation for cancer immunotherapy. |
| first_indexed | 2024-04-09T14:42:09Z |
| format | Article |
| id | doaj.art-3baf4a74bec646c1a17af2830c7a875b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-09T14:42:09Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-3baf4a74bec646c1a17af2830c7a875b2023-05-03T05:22:27ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-05-011410.3389/fimmu.2023.11647241164724Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitorKazuyuki Hamada0Kazuyuki Hamada1Junya Isobe2Kouya Hattori3Kouya Hattori4Masahiro Hosonuma5Masahiro Hosonuma6Masahiro Hosonuma7Masahiro Hosonuma8Yuta Baba9Masakazu Murayama10Masakazu Murayama11Masakazu Murayama12Masakazu Murayama13Yoichiro Narikawa14Yoichiro Narikawa15Yoichiro Narikawa16Yoichiro Narikawa17Hitoshi Toyoda18Hitoshi Toyoda19Hitoshi Toyoda20Hitoshi Toyoda21Eiji Funayama22Kohei Tajima23Kohei Tajima24Midori Shida25Yuya Hirasawa26Toshiaki Tsurui27Hirotsugu Ariizumi28Tomoyuki Ishiguro29Risako Suzuki30Ryotaro Ohkuma31Yutaro Kubota32Takehiko Sambe33Mayumi Tsuji34Mayumi Tsuji35Satoshi Wada36Yuji Kiuchi37Yuji Kiuchi38Shinichi Kobayashi39Atsuo Kuramasu40Atsushi Horiike41Yun-Gi Kim42Takuya Tsunoda43Kiyoshi Yoshimura44Kiyoshi Yoshimura45Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanDepartment of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, JapanDepartment of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, JapanResearch Center for Drug Discovery and Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, JapanDivision of Biochemistry, Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, JapanDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanDepartment of Pharmacology, Showa University School of Medicine, Tokyo, JapanPharmacological Research Center, Showa University, Tokyo, JapanDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanDepartment of Pharmacology, Showa University School of Medicine, Tokyo, JapanPharmacological Research Center, Showa University, Tokyo, JapanDepartment of Otorhinolaryngology-Head and Neck Surgery, Showa University School of Medicine, Tokyo, JapanDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanDepartment of Pharmacology, Showa University School of Medicine, Tokyo, JapanPharmacological Research Center, Showa University, Tokyo, JapanDepartment of Otorhinolaryngology-Head and Neck Surgery, Showa University School of Medicine, Tokyo, JapanDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanDepartment of Pharmacology, Showa University School of Medicine, Tokyo, JapanPharmacological Research Center, Showa University, Tokyo, Japan0Department of Orthopedic Surgery, School of Medicine, Showa University, Tokyo, Japan1Division of Pharmacology, Department of Pharmacology, School of Pharmacy, Showa University, Tokyo, JapanDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan2Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa, JapanDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan3Division of Clinical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, JapanDepartment of Pharmacology, Showa University School of Medicine, Tokyo, JapanPharmacological Research Center, Showa University, Tokyo, Japan4Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanDepartment of Pharmacology, Showa University School of Medicine, Tokyo, JapanPharmacological Research Center, Showa University, Tokyo, Japan5Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanResearch Center for Drug Discovery and Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, JapanDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanIntroductionImmune checkpoint inhibitors have had a major impact on cancer treatment. Gut microbiota plays a major role in the cancer microenvironment, affecting treatment response. The gut microbiota is highly individual, and varies with factors, such as age and race. Gut microbiota composition in Japanese cancer patients and the efficacy of immunotherapy remain unknown. MethodsWe investigated the gut microbiota of 26 patients with solid tumors prior to immune checkpoint inhibitor monotherapy to identify bacteria involved in the efficacy of these drugs and immune-related adverse events (irAEs).ResultsThe genera Prevotella and Parabacteroides were relatively common in the group showing efficacy towards the anti-PD-1 antibody treatment (effective group). The proportions of Catenibacterium (P = 0.022) and Turicibacter (P = 0.049) were significantly higher in the effective group than in the ineffective group. In addition, the proportion of Desulfovibrion (P = 0.033) was significantly higher in the ineffective group. Next, they were divided into irAE and non-irAE groups. The proportions of Turicibacter (P = 0.001) and Acidaminococcus (P = 0.001) were significantly higher in the group with irAEs than in those without, while the proportions of Blautia (P = 0.013) and the unclassified Clostridiales (P = 0.027) were significantly higher in the group without irAEs than those with. Furthermore, within the Effective group, Acidaminococcus and Turicibacter (both P = 0.001) were more abundant in the subgroup with irAEs than in those without them. In contrast, Blautia (P = 0.021) and Bilophila (P= 0.033) were statistically significantly more common in those without irAEs.DiscussionOur Study suggests that the analysis of the gut microbiota may provide future predictive markers for the efficacy of cancer immunotherapy or the selection of candidates for fecal transplantation for cancer immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1164724/fullclinical efficacygut microbiotaimmune checkpoint inhibitorsimmune-related adverse eventsPD-1 inhibitorTuricibacter |
| spellingShingle | Kazuyuki Hamada Kazuyuki Hamada Junya Isobe Kouya Hattori Kouya Hattori Masahiro Hosonuma Masahiro Hosonuma Masahiro Hosonuma Masahiro Hosonuma Yuta Baba Masakazu Murayama Masakazu Murayama Masakazu Murayama Masakazu Murayama Yoichiro Narikawa Yoichiro Narikawa Yoichiro Narikawa Yoichiro Narikawa Hitoshi Toyoda Hitoshi Toyoda Hitoshi Toyoda Hitoshi Toyoda Eiji Funayama Kohei Tajima Kohei Tajima Midori Shida Yuya Hirasawa Toshiaki Tsurui Hirotsugu Ariizumi Tomoyuki Ishiguro Risako Suzuki Ryotaro Ohkuma Yutaro Kubota Takehiko Sambe Mayumi Tsuji Mayumi Tsuji Satoshi Wada Yuji Kiuchi Yuji Kiuchi Shinichi Kobayashi Atsuo Kuramasu Atsushi Horiike Yun-Gi Kim Takuya Tsunoda Kiyoshi Yoshimura Kiyoshi Yoshimura Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor Frontiers in Immunology clinical efficacy gut microbiota immune checkpoint inhibitors immune-related adverse events PD-1 inhibitor Turicibacter |
| title | Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor |
| title_full | Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor |
| title_fullStr | Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor |
| title_full_unstemmed | Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor |
| title_short | Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor |
| title_sort | turicibacter and acidaminococcus predict immune related adverse events and efficacy of immune checkpoint inhibitor |
| topic | clinical efficacy gut microbiota immune checkpoint inhibitors immune-related adverse events PD-1 inhibitor Turicibacter |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1164724/full |
| work_keys_str_mv | AT kazuyukihamada turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT kazuyukihamada turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT junyaisobe turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT kouyahattori turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT kouyahattori turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT masahirohosonuma turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT masahirohosonuma turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT masahirohosonuma turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT masahirohosonuma turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT yutababa turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT masakazumurayama turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT masakazumurayama turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT masakazumurayama turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT masakazumurayama turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT yoichironarikawa turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT yoichironarikawa turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT yoichironarikawa turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT yoichironarikawa turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT hitoshitoyoda turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT hitoshitoyoda turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT hitoshitoyoda turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT hitoshitoyoda turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT eijifunayama turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT koheitajima turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT koheitajima turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT midorishida turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT yuyahirasawa turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT toshiakitsurui turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT hirotsuguariizumi turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT tomoyukiishiguro turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT risakosuzuki turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT ryotaroohkuma turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT yutarokubota turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT takehikosambe turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT mayumitsuji turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT mayumitsuji turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT satoshiwada turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT yujikiuchi turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT yujikiuchi turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT shinichikobayashi turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT atsuokuramasu turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT atsushihoriike turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT yungikim turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT takuyatsunoda turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT kiyoshiyoshimura turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor AT kiyoshiyoshimura turicibacterandacidaminococcuspredictimmunerelatedadverseeventsandefficacyofimmunecheckpointinhibitor |